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A mathematical model of the early inflammatory response in transplantation is formulated 
with ordinary differential equations. We first consider the inflammatory events associated 
only with the initial surgical procedure and the subsequent ischemia/reperfusion (I/R) 
events that cause tissue damage to the host as well as the donor graft. These events 
release damage-associated molecular pattern molecules (DAMPs), thereby initiating an 
acute inflammatory response. In simulations of this model, resolution of inflammation 
depends on the severity of the tissue damage caused by these events and the patient’s 
(co)-morbidities. We augment a portion of a previously published mathematical model 
of acute inflammation with the inflammatory effects of T cells in the absence of antigenic 
allograft mismatch (but with DAMP release proportional to the degree of graft damage 
prior to transplant). Finally, we include the antigenic mismatch of the graft, which leads to 
the stimulation of potent memory T cell responses, leading to further DAMP release from 
the graft and concomitant increase in allograft damage. Regulatory mechanisms are also 
included at the final stage. Our simulations suggest that surgical injury and I/R-induced 
graft damage can be well-tolerated by the recipient when each is present alone, but that 
their combination (along with antigenic mismatch) may lead to acute rejection, as seen 
clinically in a subset of patients. An emergent phenomenon from our simulations is that 
low-level DAMP release can tolerize the recipient to a mismatched allograft, whereas 
different restimulation regimens resulted in an exaggerated rejection response, in agree-
ment with published studies. We suggest that mechanistic mathematical models might 
serve as an adjunct for patient- or sub-group-specific predictions, simulated clinical 
studies, and rational design of immunosuppression.
Keywords: DaMPs, allo-recognition, ischemia/reperfusion injury, transplant, equation-based model, ordinary 
differential equations
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introduction
Solid organ transplantation represents the treatment of choice 
for end-stage organ failure-associated diseases, and has proved 
effective at extending and improving the quality of life of patients. 
Approximately 22,000 patients receive solid organ transplants 
every year in the United States, according to United Network for 
Organ Sharing1. While 1-year outcomes after solid organ trans-
plantation are excellent, the long-term outcomes are still medio-
cre, and range from 70% survival rate for kidney transplantation 
to 40–50% survival for heart/lung and intestine transplantation 
at 5  years (1–3). These poor long-term outcomes depend on 
multiple factors related to both donor and recipient, but are in 
their vast majority dictated by initial polyclonal, multimodal, and 
redundant innate and adaptive immune responses of the recipient 
directed against the allograft (4). These early immune responses 
occur both locally and systemically, in response to non-specific 
inflammatory damage-associated molecular pattern molecules 
(DAMPs) or to allo-antigen (allo-Ag)-specific major histocom-
patibility complex (MHC)-mismatch. These responses may be 
triggered by (i) the transplant surgery procedure (5); (ii) the 
type and the quality of the graft, including the level of ischemia/
reperfusion (I/R) injury (IRI) post-revascularization; and (iii) the 
level of pre-formed cellular (T cells) allogeneic and heterologous 
immunologic memory responses (4, 6).
inflammation and immunity in solid Organ 
Transplantation
While most work in the transplant field has focused on the antigen-
driven immune processes that drive graft rejection, recent work 
has begun to focus on the interplay between early innate immune 
mechanisms and subsequent antigen-driven responses (7–10). In 
this respect, the transplant community has begun to acknowl-
edge the tightly woven interplay between innate and adaptive 
immunity that has been recognized in other fields (11–20). These 
studies have pointed to multiple intersecting pathways by which 
early stress or injury leads to activation of innate and adaptive 
lymphoid pathways. Key among these pathways are those driven 
by DAMPs, which play intracellular housekeeping roles normally 
but which are released both locally and systemically upon stress, 
injury, or infection (21, 22). DAMPs activate classical innate 
immune cells such as macrophages and polymorphonuclear 
cells (PMN; i.e., neutrophils), but also stimulate dendritic cells 
(DC) to drive cytotoxic (Tc) and helper (TH) T cell activation/
polarization (23–26). In addition, non-conventional γδ-T cells, 
natural killer (NK)-T cells, as well as TH1 and TH17 cells (along 
with innate cells) provide other points of intersection between 
innate and antigen-specific (adaptive) immune responses (6, 27).
The transplantation procedure involves oxygen deprivation 
(ischemia) in the recipient host tissues as well as in the donor 
graft due to the time interval from donor organ removal to its 
placement in the recipient host. Once the transplant is complete, 
blood flow resumes, a process known as reperfusion. The I/R 
1 http://optn.transplant.hrsa.gov/
event is well-known to cause injury (IRI) to tissues, in addition 
to any direct tissue damage from the surgical procedure. These 
injurious events further initiate release of DAMPs, and this 
abates as IRI resolves (28–31). However, DAMPs initiate an 
acute inflammatory cascade involving the early expression of 
adhesion and co-stimulation molecules, chemokine release, and 
the inflammatory cytokine production by innate immune cells as 
well as memory T cells. Briefly, neutrophils respond to DAMPs 
by extruding highly inflammatory DNA material [neutrophil 
extracellular traps (NETs)] that trigger monocytes and tissue 
macrophages to secrete interleukins (IL-) IL-1β, IL-6, and tumor 
necrosis factor-α (TNF-α). In turn, these pro-inflammatory 
cytokines stimulate monocyte-derived DC to produce IL-12, 
a pivotal cytokine for generation of type-1 immunity (6, 27, 
32, 33). In addition, activated monocytes can release IL-23, a 
cytokine critical for recruitment of IL-17-producing γδ-T cells, 
responsible in turn for neutrophil chemotaxis and activation (34, 
35). As a result of the innate immune cell cytokine storm, the 
direct response to DAMPs, γδ-T cells, and memory T cells further 
contribute to IRI by IL-17 and interferon-γ (IFN-γ) release and 
costimulatory molecule up-regulation in an allo-Ag-independent 
manner (27, 36, 37).
A second layer of effector and inflammatory molecules is 
released by pre-formed alloreactive memory Type-1 and Type-
17 T cells in response to graft mismatched allo-Ag recognition. 
The levels of T cell pre-sensitization of the recipient to the donor 
correlate directly with early acute rejection episodes (38). The 
ensuing inflammation acts as a feedback loop, and may further 
cause tissue damage that drives additional release of DAMPs and 
allo-Ags. Resolution of cellular and tissue inflammation triggered 
by surgery, IRI, and subsequent DAMP release is mediated by 
innate regulatory macrophages (M2 and Mreg), intrinsic regula-
tory cytokines [IL-10, IL-4, and transforming growth factor-β1 
(TGF-β1)] along with T regulatory cells (Tregs) in animal models 
of heart, kidney, and liver transplantation (27, 39–42), while 
pre-formed alloreactive memory T cells seem less sensitive to 
regulation by Tregs (43).
These immunologic events may play a significant role in driv-
ing the diverse outcomes that accompany organ transplantation 
in various cases of apparent antigenic mismatch. We use the term 
“apparent antigenic mismatch” since the response to allo-Ag 
includes multiple factors, such as (1) actual allo-Ag differences; 
(2) individual, genetically predetermined thresholds of immune 
activation in response to a given degree of antigenic mismatch; (3) 
pre-existing levels of memory T cells; and (4) individual-specific 
response to immunosuppressive therapy.
Modern organ transplantation has utilized potent strate-
gies to control these unwanted, early immune responses. 
Specifically, thorough pre-transplant screening of recipient’s 
pre-formed donor-specific allo-antibody reactivity against the 
donor (cross-match screening for humoral sensitization) is 
combined with depleting or non-depleting induction therapy 
at organ implantation and with versatile maintenance immu-
nosuppression (44–46). All of these methods seek to mitigate 
the deleterious effects of immunity while allowing regulatory 
molecules and cells to develop. Notably, these strategies target 
mostly adaptive immune cells such as T cells, leaving the innate 
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immune players mostly unchecked. Thus, patients with elevated 
DAMP release and inflammation – due to significant IRI after 
reperfusion that carry undetected memory T cells to the donor 
MHC – may experience early rejection episodes despite proper 
pre-transplant screening, induction therapy, and maintenance 
immunosuppression. This contrasts with non-sensitized or 
minimally sensitized patients who experience minimal IRI 
due to live donation and/or optimal MHC matching, resulting 
in either indolent subclinical inflammation or in uneventful 
clinical course with desirable quiescent outcomes. For example, 
acute cellular rejection (ACR) events in the first 3 months after 
kidney transplantation occur in 10–12% of patients, while 
biopsy-proven subclinical rejection occurs in an additional 
15–18% of kidney recipients (47).
Deciphering the complexity of 
inflammation and immunity with 
Mathematical Models
The foregoing discussion suggests an emerging paradigm in 
which context and timing matter more than semantic distinctions 
among immune/inflammatory responses: in essence, inflamma-
tion/innate immunity triggers early memory lymphoid pathways 
that can subsequently become more focused after exposure to 
specific antigens, while chronic inflammation might be thought 
of as the chronic restarting of acute inflammation (48). In this 
context, attempting to define and predict responses under par-
ticular circumstances, especially in individuals, becomes almost 
overwhelmingly complex.
Mathematical modeling provides a key tool by which to study 
the integrated innate/adaptive response or acute/chronic inflam-
matory response and thereby untangle some of this complexity 
(48–50). Therefore, such models provide a means to drive novel 
hypotheses with regard to complex immune processes like those 
involved in the transplantation procedure and can assist in identi-
fying viable – and possible novel – points of control or diagnostic 
biomarkers. Multiple mathematical models that integrate innate 
and adaptive immune responses have been developed over 
the past decade to address diverse questions and disease states 
(51–54). However, a comprehensive mathematical model of 
organ transplantation is as yet lacking, and the complexity of the 
immune events involved in the procedure reiterates the need for 
such an approach. Complex systems, especially biological ones, 
are notoriously sensitive to initial conditions (55, 56). Thus, to 
address the solid organ transplant process comprehensively, we 
hypothesize the need to model not only the transplant and its 
antigenic properties, but also the initial conditions relating to the 
transplant surgery and subsequent IRI as drivers of innate immu-
nity. Indeed, prior mathematical modeling studies have suggested 
the need to model the underlying process, for example, in the case 
of the role of underlying trauma in the setting of hemorrhagic 
shock (57).
The modeling simulations in this present study suggest that 
surgical injury and graft damage can be well-tolerated by the 
recipient when each is present alone, but that their combination 
(along with antigenic mismatch) may lead to acute rejection. An 
emergent phenomenon from our simulations is that low-level 
DAMP release can tolerize the recipient to a mismatched graft 
under specific restimulation settings, while other restimulation 
regimens lead to an exaggerated rejection response.
results
To examine the early stages of inflammatory/immune responses 
to an organ transplant, including investigating the role of IRI 
in transplantation, we developed a mathematical model that 
includes the inflammatory hallmarks of IRI as well as the immune 
responses elicited by the apparent antigenic mismatch of the 
graft. As described above, we use the term “apparent antigenic 
mismatch” to comprise (1) actual antigenic differences; (2) 
individual, genetically predetermined thresholds of immune acti-
vation in response to a given degree of antigenic mismatch; (3) 
pre-existing levels of memory T cells; and (4) individual-specific 
response to immunosuppressive therapy.
The degree of this apparent antigenic mismatch is governed 
by a parameter, α, wherein a value of zero implies that the graft 
has 0% apparent mismatch with the host and a value of 1 implies 
complete (i.e., 100%) apparent mismatch. The model is initiated 
with a specified level of initial damage to the host and to the graft 
from the surgery and I/R, and thus the model simulations begin at 
approximately the time that transplant surgery is concluded (~8 h 
after the surgery begins), at which time reperfusion would occur.
In order to increase our ability to analyze qualitatively the 
driving forces behind diverse transplant outcomes, we simplify 
the number of components considered in the model and aim 
to create an abstract representation of the processes mentioned 
above. We focus on the following core scenarios and outcomes:
1. Clinical quiescence: the graft, following transplantation, 
shows no signs of inflammatory infiltrates. This is repre-
sented by model simulations showing little or no graft dam-
age and corresponding to fully or almost fully recovered graft 
functionality.
2. Acute clinical rejection: the graft, following transplantation, 
sustains levels of damage from the host response that cause 
it to lose functionality, occurring in the first 3 months after 
transplant. This is represented by model simulations showing 
high graft damage and corresponding poor graft functional-
ity very early after the simulation is initiated (i.e., after the 
transplant is completed).
3. Subclinical inflammation: the allograft, following transplan-
tation, shows no apparent clinical signs of organ damage, but 
subclinical levels of inflammation and cellular infiltrates are 
detected in the protocol biopsies in the first 3 months after 
surgery. This is represented by model simulations showing 
either stabilized but diminished graft functionality due to 
lingering inflammation, or non-stabilized, poor graft func-
tionality due to oscillating inflammatory responses driven by 
T cells.
The Mathematical Model
Figure 1 provides a schematic of all the components and inter-
actions included in the model equations. Table  1 provides a 
TaBle 1 | Dynamic model variables.
Dynamic model 
variable name
Description initial condition(s)
D Tissue damage to recipient host; measured in arbitrary units: D-units D(0) = D0 ≥ 0 due to surgery and 
ischemia reperfusion injury of host
DG Graft tissue damage; measured in arbitrary units: DG-units DG(0) = DG0 ≥ 0 due to ischemia 
reperfusion injury of graft
I Early innate pro-inflammatory components, such as tissue M1 macrophages, monocytes, 
neutrophils, TNF-α, and natural killer (NK) cells; measured in arbitrary units: I-units
I(0) = I0 = 0 in all of the scenarios 
considered
A Anti-inflammatory mediators such as IL-10 and TGF-β1; measured in arbitrary units: A-units A(0) = A0 = 0.125 maintains a 
background level at homeostasis (69)
TP Pro-inflammatory T cells such as γδ-T cells, TH1 cells, and TH17 cells; measured in arbitrary  
units: TP-units 
TP(0) = TP0 = 0
TA Anti-inflammatory T cells such as TH2 and regulatory T cells; measured in arbitrary units: TA-units TA(0) = TA0 = 0
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description of the dynamic model variables and Table 3 in the 
Section “Materials and Methods” explains the auxiliary model 
variables. The dynamic model variables are those whose rates 
change over time and are modeled with an ordinary differential 
equation (ODE); whereas auxiliary variables are functions of 
dynamic variables. We first discuss the interactions that are 
FigUre 1 | interaction diagram. The diagram provides an abstract, high-level view of the immune and inflammatory processes involved in solid organ transplant 
that we include in our mathematical model. Four dynamic immune variables are defined: I, A, TP, and TA as described in the figure legend next to their respective 
graphic marker. Also tracked is host tissue damage and graft tissue damage via the dynamic variables, D and DG, which are represented in the diagram by the 
shape labeled “Surgical, Ischemia/Reperfusion, and Graft Injury” at the top of the diagram, along with DAMP release as a result of this injury. Arrows represent 
induction/activation of a target variable (connected at the arrow head) by an initiating variable (connected at the arrow tail). Inhibitory effects are indicated by the 
presence of an inhibitory variable marker resting atop the middle part of an arrow. For example, A inhibits the activation of I from DAMPs released by tissue damage. 
Multiple arrows coalescing into a target variable at the same point indicate that all initiating variables are required to complete that particular induction/activation 
process. For instance, I and A are both needed to activate TA. Circulating/resting source populations of T cells and innate immune components, T0 and IR, 
respectively, are required for all processes that induce/activate these into the variables TP or TA and I, respectively. To keep the diagram uncluttered, the source 
populations are not shown in all of the processes in which they are required. Instead a representative example is given for each, as seen in the activation of IR into I 
by TP and in the activation of T0 into TP (alternatively, into TA) by TP (alternatively, by TA). The presence of allo-Ag of the graft is indicated with a red cross and 
represents another excitatory factor of the pro-inflammatory arms of the system as is the DAMP release by damaged tissue. Some activation processes require the 
presence of allo-Ag and these are represented by a red cross at the initiating (tail) end of an arrow.
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pro-inflammatory and then discuss how these processes initiate 
and/or are inhibited by the anti-inflammatory components, all 
based on the immunology discussed in Section “Inflammation 
and Immunity in Solid Organ Transplantation.” The model does 
not currently take into consideration explicitly the immuno-
suppressive therapies given before/during the transplantation 
procedure, though the effect of immunosuppression is in a sense 
contained in the concept of apparent antigenic mismatch. We 
envision testing specific immunosuppression mechanisms (e.g., 
killing of all inflammatory cells vs. specific killing of T cells) in 
future iterations of this model.
The goal of this modeling exercise is to understand the dynam-
ics of the transplant procedure from a more abstract perspective, 
in which we group multiple components into a single variable. 
While this level of abstraction will in no way allow a quantitative 
prediction of specific mediators and cells, this approach does 
allow for an examination of the overall qualitative dynamics 
of this system in which excitatory and inhibitory mechanisms 
interact. The early innate components of the model, denoted by 
the variable I, incorporate the general pro-inflammatory effects 
of cells such as tissue-resident M1 macrophages, circulating 
monocytes, neutrophils, and NK cells as well as cytokines such 
as TNF-α, IL-6, IL-1β, IL-12, and IL-23. Pro-inflammatory 
T cells are represented by the variable TP, and incorporate the 
general properties of γδ-T cells, TH1, and TH17 T cell subsets. 
Also included are anti-inflammatory components, denoted by A, 
which include M2 macrophages, IL-10, and TGF-β1. In addition, 
anti-inflammatory T cells are denoted by the variable TA and are 
comprised of T regulatory and TH2 T cells. There are also two 
dynamic variables that track the rate of change of tissue dam-
age: one for host tissue, denoted by the variable D, and another 
for graft tissue, denoted by the variable DG. These six dynamic 
variables are modeled with ODEs that describe how the rates of 
these entities change over time as they interact with one another 
under different simulation scenarios. The variables have arbitrary 
units, as we are not aiming to match them with quantitative data 
but instead examine their dynamic behavior. The time scale is in 
hours. Whereas some parameters governing the various rates of 
the interactions are estimated from the literature when possible 
(e.g., from half-lives of cells and inflammatory mediators), the 
parameters are largely estimated to constrain the model to display 
basic biologically feasible behavior; see Section “Materials and 
Methods” for more information.
Figure 1 shows that D and I interact in a positive feedback loop 
that is inhibited by A. This models the effect of DAMPs released by 
tissue damaged due to IRI. This process is driven by early innate 
immune components, resulting in the activation of pro-inflam-
matory components from a resting/circulating population, IR (5). 
These activated pro-inflammatory components cause further tis-
sue damage; but the activation is inhibited by anti-inflammatory 
influences in a “checks-and-balances” manner. However, severe 
damage can cause an unabated positive feedback loop among 
these components, resulting in an unresolved response (31, 57). 
In the absence of graft placement (i.e., considering the surgical 
procedure alone), the innate pro-inflammatory components can 
also induce pro-inflammatory memory T cell recruitment from 
a circulating T cell population, T0 (9, 58). In the presence of the 
anti-inflammatory components, A, the innate components, I, can 
induce Tregs and TH2 cells, represented by TA. Many of these 
activation/induction processes are inhibited by either A or TA 
(27, 41, 59–61). This describes the interactions surrounding the 
surgical procedure and IRI of the host.
When a solid organ is transplanted, we considered that it 
would have some initial IRI due to the removal and transport 
procedures. In addition, the organ could subsequently be dam-
aged by the pro-inflammatory components (both innate and T 
cell-mediated) present at the transplant site, even in the absence 
of allo-Ag (58). We model graft functionality (percent), G, as 
a function of this damage, DG (see Table  3 in “Materials and 
Methods”). Subsequently, we include a parameter (α) governing 
the mismatch factor to scale the response from innate and T 
cell pro-inflammatory components in response to an allograft. 
Figure 1 also shows that graft injury can release DAMPs, which 
in turn can activate innate immune components as discussed 
above. Furthermore, the presence of a graft with a positive anti-
genic mismatch factor, governed by the parameter α, will cause 
antigen-specific memory T cells to infiltrate and cause further 
injury to the graft. This process is modeled by a gain to DG. This 
damage will reduce graft function, G, as illustrated in the inset 
figure of Table 3, and consequently will reduce the percentage of 
graft tissue available to harm further.
With a positive graft mismatch factor, the early innate pro-
inflammatory components, such as monocytes and M1 mac-
rophages, through allo-recognition, will provide additional and 
specific activation via DC of the pro-inflammatory memory 
T cells, TP (10, 58). This process is indicated in Figure  1 by 
the arrow coming from I into TP, with the apparent host–graft 
mismatch marker (red plus sign) present at the tail end of the 
arrow. In keeping with the abstract model representation of 
these processes, we do not include the DC component directly, 
yet the process is implicit in the interactions. Additionally, a 
positive graft mismatch factor will enhance further recruitment/
activation of both pro- and anti-inflammatory T cells, from the 
source T cell population, T0, by already activated components 
of these types. Again, various processes are inhibited by A and/
or TA, as indicated in the legend of Figure 1 by an induction 
arrow that has a particular variable marker sitting atop it in 
the middle.
In the Section “Materials and Methods,” the construction of 
the model is discussed and the full model is given by Eqs 1–6, 
with the model parameter descriptions and values used in the 
simulations given in Table 4. The equations are solved numeri-
cally to produce time courses of each of the system variables or 
states (see Materials and Methods). These resulting time courses 
are translated to clinical outcomes in the following manner. In 
general, we define a pre-surgery initial condition for the model 
variables as (I0, D0, A0, DG0, TP0, TA0) = (0, 0, 0.125, 0, 0, 0), which 
indicate that all system components are at their background 
values. This state is referred to as the baseline equilibrium. This 
setting assumes that there are no underlying immune conditions 
prior to transplant surgery, which is typically not realistic in 
the case of transplant recipients. Future iterations of the model 
could incorporate prior host health conditions. The system can 
be perturbed from this baseline state, for instance, by setting a 
FigUre 2 | simulation results of the inflammatory cascade following transplant surgery only without graft placement (i.e., G = 0). (a–D) Below a 
certain threshold, initial host tissue damage caused by IRI incites an inflammatory response that resolves to baseline levels. Initial condition for this simulation was (I0, 
D0, A0, DG0, TP0, TA0) = (0, 3, 0, 0.125, 0, 0) with parameters as given in Table 4. For D < 4, this outcome is possible. (e–h) Above a certain threshold, initial host 
tissue damage caused by IRI incites an inflammatory response that does not resolve and results in host health failure. Note that this scenario is not the one we 
would consider for transplant conditions, but demonstrate the scope of the model dynamics to produce theoretically possible outcomes of traumatic injury. Initial 
condition for this simulation was (I0, D0, A0, DG0, TP0, TA0) = (0, 4, 0, 0.125, 0, 0) with parameters as given in Table 4. For D ≥ 4, this outcome is possible.
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non-zero initial condition for D and/or DG, which indicates the 
presence of damaged tissue to host and/or graft, respectively, 
due to IRI. The rates at which system variables change as a func-
tion of time are governed by the Eqs 1–6. A simulation in which 
the variables’ time courses return to the background levels, after 
a brief transient increase away from this state due to perturba-
tion, is translated as a healthy outcome. Figures 2A–D display a 
basic healthy outcome scenario in terms of host health.
On the other hand, an unhealthy outcome is presumed if the 
departure away from the healthy equilibrium is not transient but 
instead causes the variables to approach a different equilibrium 
that has elevated levels of the variable states. The unhealthy 
equilibrium implies host health failure and, when a graft is con-
sidered, graft failure as well. Alternatively, one could define a level 
of cumulative damage that could be considered as irreparable, 
rather than defining non-recovery only by the system’s long-term 
behavior; we did not explore this possibility in the present study. 
Figures  2E–H display a basic unhealthy outcome scenario in 
terms of host health. When a graft placement is considered (with 
and without apparent mismatch), outcomes also include the per-
cent graft functionality, where a steady-state graft functionality 
value of 12% represents outright graft failure. See Figures 3A–D, 
for instance.
simulation: ischemia/reperfusion injury Without 
graft Placement (i.e., G = 0)
As a first scenario, we consider only the aspects of the inflamma-
tory response of the host involved during the surgical transplant 
procedure in the absence of a graft placement. This scenario could 
also be viewed as a look at the trauma of transplant surgery or 
an instance of accidental blunt trauma, in general. To simulate 
this situation, we set the initial condition for the host damage 
variable, D, to a non-zero value, and remove the presence of the 
graft, G, from the model. All other variable initial conditions 
FigUre 3 | simulation results of the inflammatory cascade following transplant surgery and non-allo-ag graft placement (i.e., α = 0). Combined initial 
host and graft IRI can synergize to incite an inflammatory response that (a–D) cannot resolve, causing graft failure or (e–h) transiently decrease graft function 
significantly. (a–c) present a series of simulations in which (a) a moderate level of initial surgical IRI in the host is considered with no corresponding graft IRI 
associated with the placement, (B) no initial surgical IRI in the host is considered with a low level of initial graft IRI, or (c) the moderate level of initial surgical IRI in 
the host of simulation (a) is coupled with the low level of initial graft IRI of simulation (B). In (D), the graft functionality curves corresponding to simulations (a–c) are 
shown. The “Graft function for C” time course in (D) displays the synergy to severely affect graft function such that the graft fails, shown as functionality decreasing 
to and remaining at 12%. Similarly, panels (e–g) display outcomes for (e) a low/moderate level of initial surgical IRI in the host with no corresponding graft IRI 
associated with the placement, (F) no initial surgical IRI in the host with a corresponding moderate level of initial graft IRI, or (g) the combination of the low/moderate 
initial level of surgical IRI in the host from simulation (e) with the moderate level of initial graft IRI from simulation (F). In (h), the graft functionality curves 
corresponding with (e–g) are shown. The “Graft function for G” time course in (h) displays the synergy to significantly affect graft function, but only transiently after 
which the graft functionality fully recovers. Initial conditions for (c): (I0, D0, A0, DG0, TP0, TA0) = (0, 3, 0.5, 0.125, 0, 0); initial conditions for (g): (I0, D0, A0, DG0, TP0, 
TA0) = (0, 2, 1, 0.125, 0, 0).
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are set to their healthy state baseline values. Figures  2A–D 
show that an inflammatory response is incited (e.g., levels of I, 
etc. increase from baseline values) for some initial level of host 
tissue injury corresponding to DAMP release. We note that this 
response resolves completely in a reasonable time frame. In other 
words, the inherent inhibitory mechanisms provided by the anti-
inflammatory variables, A and TA, are sufficient to regulate the 
response correctly. However, in Figures  2E–H, the initial level 
of IRI was high enough to cause irreparable damage, an unlikely 
situation in today’s modern operating theater, yet a theoretically 
possible outcome. Thus, our model displays feasible qualitative 
behavior related to surgical trauma.
simulation: ischemia/reperfusion injury with 
graft Placement But with no apparent antigenic 
Mismatch (i.e., α = 0)
The next iteration of simulations considers not only the IRI to 
the host from surgery but also the IRI associated with the graft 
due to the processes of harvest from donor and transportation 
to the recipient host. We assume that initial graft functionality 
starting at a percentage lower than 100% is a result of IRI due 
to the harvest and transport procedures, and not an indicator 
of the functionality that it had when still intact in the host 
from whom the graft was harvested. Thus, 100% in our model 
would mean 100% of the total functionality exhibited by a 
FigUre 4 | simulation results showing outcomes of transplant surgery with placement of allo-ag graft for various degrees of apparent mismatch 
(i.e., α > 0). The initial condition used in Figure 3g [i.e., (I0, D0, A0, DG0, TP0, TA0) = (0, 2, 1, 0.125, 0, 0)] was also used here but now various values of the apparent 
mismatch factor parameter, α, were explored to observe the effects of initial host and graft tissue damage from IRI in conjunction with allo-recognition. (a) With low 
mismatch factor (α = 0–0.03), graft tolerance is seen. (B) Within a higher range (α = 0.04–0.25), damped oscillations in graft functionality appear but resolve to 
greater than 95% functionality in the long term with values of α on the higher end of the range taking months to resolve and stabilize. (c) Within the next highest 
interval (α = 0.29–0.5), undamped oscillations are apparent. This indicates a regime where graft function is affected by chronic inflammation driven by T cells that 
flares up and subsides periodically. (D) The last interval (α = 0.55–1.0) displays acute graft failure within 400 h for α values near the minimum of this range and within 
125 h near the maximum of this range.
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given organ pre-transplant. Presumably, organs harvested 
for transplant were functioning “normally,” such that they 
did not have existing damage affecting this normal function. 
However, this value could be lower if an organ were harvested 
from an older or less healthy donor (a scenario we did not 
explore explicitly). For this simulation set, we assume that the 
graft and host are identical, and therefore do not consider any 
interactions that involve allo-recognition due to mismatch 
(i.e., the parameter governing mismatch intensity is set to zero: 
α = 0). The model also displays feasible qualitative behavior 
for possible outcomes when considering ranges of injury 
severity. In Figures 3A–D, we show that initial host damage 
combined with initial graft damage can synergize to result 
in graft failure, whereas each of these challenges separately 
did not. Figures  3E–H show synergy as well, but in a less 
extreme manner, wherein the graft does not fail and recov-
ers fully. However, as seen in Figure 3H, the time course for 
“Graft Function for G” shows that the negative effects on graft 
function from IRI reduce graft function by 60% at one point 
in the simulation. This result suggests that the non-specific, 
detrimental effects of inflammatory processes initiated by IRI 
may make the graft that much more vulnerable in cases where 
host–graft mismatch is considered. We explore mismatch 
scenarios in the next two sections.
simulation: ischemia reperfusion injury with 
graft Placement and Varying apparent antigenic 
Mismatch levels (i.e., α > 0)
In this next simulation set, we consider varying levels of host–graft 
mismatch, and thus the interactions shown in Figure 1 involving 
allo-recognition come into play. We use the initial condition 
(I0, D0, A0, DG0, TP0, TA0) = (0, 2, 1, 0.125, 0, 0) as in Figure 3G, and 
set α to different values within the interval [0,1] in the multiple 
simulation runs. Figures 4A–D display four qualitatively differ-
ent outcome scenarios corresponding to ranges of the mismatch 
parameter, α. Each figure panel displays the graft functionality 
results of multiple simulation runs for values of α within the 
specified ranges. In these various scenarios, we observe outcomes 
corresponding to the clinical scenarios mentioned earlier at the 
beginning of Section “Results.” Clinical quiescence is represented 
in Figure 4A, where there is little or no graft damage and full 
or nearly full graft functionality is achieved and retained. Acute 
clinical rejection is represented in Figure 4D, where poor graft 
functionality is seen very early after the simulation is initiated 
(i.e., after the transplant is completed), and failure is predicted to 
occur within less than a month’s time. The subclinical inflamma-
tion outcome is represented in Figures 4B,C. In Figure 4B, we 
interpret the smaller oscillations as subclinical chronic inflamma-
tion predicted to resolve on the order of 1–3 months (shown for 
TaBle 2 | Minimal initial graft function required for graft survival given a 
particular mismatch intensity factor.
Value of α Minimal graft 
functionality percent  
[or Dg(0) value]
ending graft functionality 
percentage (steady state 
value of G)
0 20% (or 1.9) 100%
0.1 20% (or 1.9) 99%
0.2 20% (or 1.9) 97%
0.3 20% (or 1.9) 75–97% oscillation range
0.4 20% (or 1.9) 48–99% oscillation range
0.5–0.6 20% (or 1.9) 38–99% oscillation range
0.7 24% (or 1.8) 27–99% oscillation range
0.8–1.0 No cutoff exists Graft failure (13%)
Ending graft functionality percentages are with respect to an initial assumed 100% 
functionality that a given organ had pre-transplant, as explained in Section “Simulation: 
Ischemia/Reperfusion Injury with Graft Placement But with No Apparent Antigenic 
Mismatch (i.e., α = 0).”
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up to 1000 h ~ 42 days), since the recovery behavior is different 
from, and takes longer than, the graft tolerance recovery scenario 
of Figure 4A. Furthermore, since in Figure 4B the damped oscil-
lations are such that (1) graft health does not decrease too often 
nor too greatly below the original graft health level; and (2) an 
acceptable recovery is seen eventually (i.e., graft health is greater 
than 95%), we interpret this behavior as subclinical. In other 
words, the graft is in comparable or better condition than when it 
was first transplanted, but it is not maintaining optimal function 
until much later. Note that Figure 4A could also be classified as 
subclinical, but the length of time in which graft health is not ideal 
is much shorter relative to the scenarios in Figure 4B. Thus, we 
do not classify Figure 4A as a chronic scenario. In Figure 4C, the 
oscillations are larger and do not resolve as in Figure  4B. We 
equate this outcome with long-term rejection since a high and 
steady level of graft function is never observed as T cells cause 
inflammation and subsequent damage to flare up and subside 
repeatedly. This prediction points to a scenario leading to graft 
failure, even though there are times when there is only subclinical 
inflammation, and a good level of graft function is observed.
Table 2 displays a summary of minimal initial graft functionality 
percentages (corresponding to an initial value of DG) from which 
outright graft failure (i.e., ending graft functionality of 12%) is 
avoidable, given a particular value of α. For ~0.032 < α < ~0.3, the 
healthy stable equilibrium is replaced by a suboptimal healthy stable 
equilibrium. Higher α values outside this range give rise to oscilla-
tions that indicate worsening graft function, with the minimal graft 
functionality of the oscillatory range reaching 27% as α approaches 
0.7. For α > ~0.75, outright graft failure is the only outcome and the 
ending graft functionality equilibrium value is 12%.
simulations of Preconditioning scenarios
In some simulations, an initial level of host tissue damage can act 
as a preconditioning factor in promoting graft survival. While the 
release of DAMPs from injured tissue incites pro-inflammatory 
components, the cascade also involves induction of anti-
inflammatory mediators. If the pro-inflammatory levels from this 
initial surgical DAMP release are below some threshold, and the 
corresponding anti-inflammatory cell/mediator levels are above 
some threshold at the time the additional DAMP release happens 
from an IR-injured graft, then an attenuated damage response 
may be possible. We depict one such simulation experiment of 
this preconditioning phenomenon, shown in Figure 5. This type 
of preconditioning, in which the response to a second insult is 
lower than that for the first, is called “tolerance” and has been 
reported widely in multiple settings of acute inflammation (62, 
63). Indeed, a similar tolerance phenomenon was reproduced in 
a mathematical model of the host immune response to repeated 
endotoxin challenge (64). That study also demonstrated that 
repeated endotoxin challenges that were not timed carefully 
displayed potentiation of the inflammatory response, another 
manifestation of preconditioning typically known as priming 
(65). The analogous potentiation feature was seen in the present 
model in Figure 3D even with no mismatch factor present. We 
interpret this outcome to be similar to the scenario in which a graft 
is rejected, and the patient undergoes repeat transplantation. The 
outcomes in this setting are known to be poor (44, 66). Thus, the 
timing of the excitatory and inhibitory mechanisms involved in 
the entire transplant process is important to understand in order 
for therapeutic strategies to positively synergize with these events.
Discussion
The integrated nature of inflammatory and antigen-specific 
immunity that underlie the response to organ transplantation 
has largely defied a synthetic understanding. This complexity can 
often be observed in the form of emergent phenomena that can-
not be predicted based on an understanding of the component 
parts of the immune system, and may be at the root of the need 
for life-long immunosuppression post-transplantation. We sug-
gest that the development of novel treatment strategies for organ 
transplantation can be aided greatly by mechanistic mathemati-
cal models such as the one presented here, because inevitably, 
independent mechanisms must be integrated in order to predict 
higher-order system properties in a clinically relevant manner. 
We regard a mechanistic model as one that describes “rules” for 
how the individual model components interact and evolve with 
time. We use the term “mechanistic” to distinguish this type of 
model from statistical or data-driven models, in which quantita-
tive associations are defined, rather than abstracted mechanisms.
The past decade has witnessed such a synthesis in the form of 
simplified (reduced-order) computational models of acute inflam-
mation, which have yielded useful insights into the mechanisms 
and pathophysiology of critical illness (64, 67–69). However, such 
models are at best only capable of general, high-level predictions, 
which are not sufficiently specific so as to be testable in individual 
patients or in in vitro/in vivo experiments. Alternatively, modeling 
biological systems in a realistic fashion often necessitates complex, 
large-scale models describing the underlying system dynamics 
(54, 70, 71). An important advantage of such mechanistic models 
is that they can allow for quantitative predictions (48, 49, 56, 
72–76) and clinically translational connections of molecular 
mechanisms to pathophysiology (77), with the ultimate goal of 
improving the drug development process (78).
Mechanistic models have helped suggest the central role of 
DAMPs in acute inflammation (49, 75–76, 79–84). Mechanistic 
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modeling has also helped elucidate the forces driving inflam-
matory preconditioning, namely the different inflammatory 
responses that ensue when multiple stimuli are given in succes-
sion (64, 85–90). Other applications of mechanistic modeling 
involve the understanding of multifactorial therapies for acute 
inflammatory diseases (91, 92). Key translational applications 
such as in  silico clinical trials based on mechanistic models of 
inflammation and damage/dysfunction were pioneered in the 
arena of acute inflammation (71, 93, 94). These models have 
grown in sophistication, and are beginning to show the potential 
for predicting the inflammatory responses of large, outbred 
animals (78, 95, 96) and individual human subjects (71, 97, 98).
The unmet need for new treatments and diagnostic modali-
ties allowing ultimately for long-term graft survival with low 
or no immunosuppression in organ transplantation is acute. 
While decades of work have led to many novel insights from the 
molecular to the physiological level, the net result has remained 
centered around life-long immunosuppression. We suggest that 
this is not because the effort has not been worthwhile or because 
promising candidate approaches were not pursued. Rather, it is 
our contention that what has not taken place is the process of 
synthesis of these insights into a larger whole. Computational 
modeling is a promising avenue for such synthesis; however, the 
current approach is based purely on statistical tools by which to 
associate multiple variables to outcomes.
In the present study, we created a mechanistic mathematical 
model based on ODEs that describe key mechanisms of innate 
and adaptive immunity and that span the full process of trans-
plantation. This model focuses on the very early inflammatory 
events linked to the surgery, IRI, and memory T cell attack, 
events cross-modulated by each other and which translate into 
significant subclinical and clinical manifestations in only a subset 
of organ transplant recipients. However, these complex, early 
inflammatory events, as they do occur, may set the tone for either 
excellent or poor long-term allograft and patient outcomes. Thus, 
key outputs of our model include the prediction of that surgical 
injury and I/R-induced graft damage can be well-tolerated by the 
recipient when each is present alone, but that their combination 
(along with antigenic mismatch) may lead to acute rejection, as 
seen clinically in a subset of patients (38, 47). An emergent phe-
nomenon from our simulations is that low-level DAMP release 
can tolerize the recipient to a mismatched allograft, whereas 
different restimulation regimens can drive an exaggerated 
rejection response. This former prediction is in agreement with 
published studies showing that preconditioning with the DAMP 
high-mobility group box 1 (HMGB1) can reduce the severity of 
inflammation and damage in the setting of graft IRI (99).
Limitations of this mechanistic mathematical model reside 
in the fact that the induction therapy and the maintenance 
immunosuppression are not considered in the model, and this is 
an area for expansion and augmentation of our modeling work. 
Moreover, this mechanistic mathematical model that predicts 
early innate and adaptive immune events is a generic one: each 
organ may have its own distinctive signature of early immune 
events. Thus, further augmentation of our model would involve 
making organ-specific variants. Additional limitations include 
the fact that this is a relatively abstract model, in which multiple 
mechanisms are lumped into single variables. As such, this model 
cannot be directly verified in a quantitative manner, other than as 
concerns the relative timing of various events. One key area where 
this limitation is apparent concerns the aforementioned emergent 
tolerization behavior as a function of prior exposure to damaged 
graft tissue, which we hypothesize as being due to DAMPs such 
as HMGB1 (99). Given tolerization is a manifestation of similar 
mechanisms to those that drive injury, and that HMGB1 can drive 
hepatic injury through activation of DCs (100), it is tempting 
to speculate that DCs are a key cell type in this process. Thus, 
future modeling work focused on examining this tolerization 
mechanism (or alternative mechanisms) in the context on organ-
specific environments is warranted. In addition, a greater in-depth 
mathematical analysis can be done to gain deeper insights into the 
dynamics, which becomes especially helpful when the models are 
more closely tied to experimental and clinical data.
Despite these limitations, this model was capable of reproduc-
ing a rich set of biological and clinical behaviors. Simulations of 
this model under various initial conditions of IRI, graft injury, and 
degree of antigenic mismatch yielded a broad spectrum of out-
comes from nearly complete graft function to outright (acute or 
chronic) rejection. Importantly, this model also yielded behaviors 
such as tolerization (durable unresponsiveness to donor-antigens) 
through preconditioning, as well as the harmful alternative out-
come of more severe graft failure upon retransplantation. Future 
iterations of this model could address these limitations and addi-
tionally explore the effects of variability that would naturally exist 
from patient to patient with respect to host health and immune 
function (94). Consequently, mathematical/engineering control 
methodologies could be employed on the models to suggest early 
therapeutic intervention strategies for this complex immune 
system (101).
In conclusion, we suggest that this model is a stepping stone 
toward further insights, not only into the response to allotrans-
plantation but also for other disease states. Several diseases with 
or without an immunologic trigger have been recently deter-
mined to have inflammation as a common fingerprint. Therefore, 
understanding diseases according to their common biological 
mechanism and using systems biology, mathematical modeling, 
and bioinformatics/data-driven modeling methods to interrogate 
the immune response before, during, and after perturbation will 
help not only to predict clinical outcomes but also guide prompt 
and precise targeting of new therapies (46, 102).
Materials and Methods
We formulate the model by building upon the approach and 
principles of prior modeling work to provide the foundation 
for the current model (64, 69). In this prior work, an abstract, 
four-equation model of the acute inflammatory response to 
bacterial pathogen and to Gram-negative bacterial endotoxin was 
developed. The approach considered various subsystems as a way 
to tractably analyze and calibrate the qualitative behavior of parts 
of the larger system to gain a greater understanding of which enti-
ties governed certain dynamic properties in the larger system. 
We refer to this modeling process as a “subsystem modeling 
approach.” The Reynolds et al.’s model displayed rich qualitative 
FigUre 5 | Preconditioning phenomena: initial surgical iri allows damaged graft to recover compared to scenario wherein graft failure occurs in the 
absence of initial surgical damage. (a) Graft functionality with (blue) and without (red) an initial level of host I/R damage, D(0). Initial graft damage [DG(0) = 2] 
along with a low initial level of host tissue damage [D(0) = 1] results in graft recovery to full functionality (blue); whereas initial graft damage [DG(0) = 2] without the low 
initial level of host damage [D(0) = 0] leads to graft failure (red). (B) The anti-inflammatory components, A, and (c) anti-inflammatory T cells, TA, with (blue) and 
without (red) an initial level of host IRI, D(0). Comparing the red and blue time courses for both anti-inflammatory variables (A and TA) in (B,c), one observes a slight 
increase in levels (blue above red) in the first 24 h or so. This increase in the anti-inflammatory variables (especially of A) induced by the very inflammatory cascade 
that was due to DAMP release actually allows for graft survival.
September 2015 | Volume 6 | Article 48411
Day et al. Modeling the dynamics of allo-recognition in organ transplantation
Frontiers in Immunology | www.frontiersin.org
behavior that corresponded to multiple clinical outcomes seen in 
cases of severe systemic inflammation due to bacterial pathogen 
and experimental studies of endotoxemia and tolerance. The gen-
eral dynamical components of this prior model, when considered 
without a pathogenic or endotoxin insult, also correspond well to 
an abstract representation of the immune response to traumatic 
insult. Thus, the current model adopts a similar strategy and 
mindset for the development of the current model of immune 
responses in transplantation.
All model simulations and analysis were performed with 
XPPAUT (103). To create Figures  2–5, the numerical data 
produced from the XPPAUT simulations were exported to 
MATLAB® (R2013b, The Mathworks Inc., Natick, MA, USA). 
Additional calculations were performed with MAPLE (2015, 
Maplesoft™, Waterloo, ON, Canada). The complete math-
ematical model given by the ODE system (1)–(6) was analyzed 
using the subsystems approach mentioned above wherein the 
dynamics of a few interacting variables are examined prior to 
combining the equations altogether. Parameter values used 
in this section can be found in Table 4. In the subsystems we 
discuss throughout this section, of most interest is the number 
and stability properties of equilibria and how these change with 
parameter value changes. Equilibria of a system of differential 
equations occur at the intersections of nullclines which are the 
equations resulting from setting each differential equation to 
zero and solving the resulting system of algebraic equations. The 
points that satisfy this are naturally the system states at which 
there is zero rate of change e.g.,dx dt =( )0 , indicating an equi-
librium state or fixed point. The dynamics of the ODE system 
are organized around these special points. For a system of two 
variables, the nullclines are especially useful for a geometric 
analysis of the system states and to observe how the shapes and 
positions of the nullclines change with changes to parameters 
or functional forms of the equation terms. Small perturbations 
of the system away from an equilibrium that cause the system 
solutions to return to the equilibrium as t→∞ define a locally 
asymptotically stable (or simply stable) equilibrium. If, on the 
other hand, the perturbation causes solutions to move away 
from said equilibrium, then we call the equilibrium unstable. 
We only concern ourselves with biologically feasible equilibria 
which are those in the positive orthant. The variables of the 
system are necessarily formulated to remain positive for all time 
and all parameters are positive as well. For more details regard-
ing the terminology and mathematical analysis used, consult 
for instance (104).
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DTotal/I subsystem: Total Damage and early 
innate components
We will first consider a subsystem that examines the dynamics 
of tissue damage and associated DAMP release with the early 
innate components of interest herein, as described in Table 1. 
In (69), it was shown that a similar subsystem involving 
damage and early pro-inflammatory phagocytes contained a 
stable healthy equilibrium as well as another stable equilibrium 
corresponding to elevated damage and elevated immune 
components. We build upon the structure developed there to 
construct our subsystem here and discuss the resulting analysis 
afterward. We note that the terms contained within the ODEs 
that we formulate are based on the principle of mass action 
kinetics. For instance, Table 5 provides the system of reactions 
involving the resting/circulating innate components, IR, and 
the activated innate components, I. Table 3 then provides the 
details on how we use a quasi-steady-state assumption to reduce 
the IR/I system to a single equation, based on the rapid nature of 
the activation process.
For the analysis of the DTotal/I subsystem, we model the 
activation of resting/circulating pro-inflammatory innate com-
ponents as described in Section “Deciphering the Complexity 
of Inflammation and Immunity with Mathematical Models” but 
ignore for now any inhibitory effects from anti-inflammatory 
components or additional activation by pro-inflammatory T cells 
and thus arrive at Eq.7.
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TaBle 3 | auxiliary model variables.
auxiliary variables Variable description, equation, and modeling explanation
IR Resting/Circulating population of I components, such as neutrophils and monocytes, from which the I population is activated. When 
the IR population is activated into I, via DAMPs for example, we assume that the activation is rapid and employs a quasi-steady state 
assumption. (See Table 5 for reactions governing IR and I.) The result is incorporated into the equations in which IR appears. (arbitrary 
units: IR-units)
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2  which incorporates the inhibitory effects of the anti-inflammatory mediators, 
represented in the variable, A, on the activation of I.
T0 Population of inactivated memory T cells from which the T cell subsets, TP and TA, are produced. The T0 population is also assumed to 
be in quasi-steady state and the result is incorporated into the equations in which T0 appears. (arbitrary units: T0-units)
T
k T G k I k I G ktaia
0
1
=
+
⋅ + + + ⋅ + ⋅ +
s T
A I k
t0 A
0
( )
(α µ α αtat0g A t tpi tpig tpt0g P AT G)( )⋅ +1 T
,
derived from assuming that the following equation is in quasi-steady state:
dT
dt
0
t0 t0 tpi tpig tpt0g P tai= − − ⋅ − ⋅ ⋅ − ⋅ ⋅ −s T k I T k T I G k T T G k Aµ α α0 0 0 0 ⋅ ⋅ − ⋅ +
I T k T G
T
T0 1
α tat0g 0
A
A
.
G Graft health/functionality; measured as a percentage with 0 indicating 0% functionality  
and 1 indicating 100% functionality. Graft health is defined as a function of  
associated graft damage, DG:
G
e
k e
= −
−
+
1
1
1
-DG
xgdg
-DG
xgdg
gdg .
[Frame1]The parameters kgdg and xgdg scale the level of the variable DG to relate it to the  
loss of graft functionality, denoted by the term −
−
+
1
1
e
k e
-DG
xgdg
-DG
xgdg
gdg
in the equation for G.  
See inset figure for an example response curve of G.
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dD
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Total
di
Gain from effects
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host tissue
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r/regeneration
dig
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I G   + ⋅ ⋅k f ( )
rly innate
components on
graft tissue
  
,
 (8)
 
where 
di
f x x
x x
( ) .=
6
6 6+  
The total tissue damage can be modeled by combining tissue 
injury caused (a) to host tissues from the early innate components 
responding to DAMP release and (b) to the graft, G, by either 
early innate components, I, or by pro-inflammatory T cells, 
TP, the latter of which is ignored for the analysis of the DTotal/I 
subsystem. Thus, we formulate Eq. 8, where a decay term of the 
total damage is also incorporated to account for a combination 
of tissue repair and regeneration. Graft health, G, is a function of 
graft damage, DG as discussed in Table 3. Note that since Eq. 8 is 
for total damage and not just graft damage, the parameters kgdg 
and xgdg have a slightly different meaning in this subsystem than 
they will in the full system, where the DTotal equation is separated 
into two equations: one to represent the damage to the host, 
D, and another to represent the damage to the graft, DG. This 
separation is done later in order to distinguish between damage 
done in general and graft-specific damage. Additionally, the 
inhibitory effects of anti-inflammatory components, A and TA, 
are later incorporated as is the additional damage to graft tissue 
by activated pro-inflammatory T cell subsets, TP.
As in (69), we assume that the ability of the innate immune 
components to create damage saturates when these components 
are very large relative to their baseline levels. We also incorporate 
the Hill-type function given as f(x) under Eq.  8 with a hill-
coefficient of 6. We note that the choice of a hill coefficient in 
Reynolds et al. was made to ensure that the healthy equilibrium 
of the subsystem has a reasonable basin of attraction. Using the 
parameter values given in Table 4, this modified system behaves 
as in the prior work, with the I and DTotal nullclines intersecting 
at (0,0) and at two additional points in the positive quadrant. The 
“healthy equilibrium” (DTotal,I) =  (0,0) is locally asymptotically 
stable when µ >
µi
ir ii
ir
s k
, which is the same criteria reached in (69) 
for the analogous parameters, even with the modifications made 
for this current focus. Furthermore, an unstable saddle equilib-
rium separates the basins of attraction of the healthy equilibrium 
and the other stable equilibrium (DTotal,I)≈(1.2,17.5), as observed 
in the prior work. Thus, the underlying structure of bi-stability is 
TaBle 4 | Model parameters.
name Description/source Value/units name Description/source Value/units
kii* Activation of innate components by previously activated innate  
pro-inflammatory components
0.01/I-units/h Sa* Source term for anti-inflammatory components (A) 0.0125 A-units/h
Sir* Source of resting/circulating inactivated innate pro-inflammatory 
components
0.08 IR-units/h kai* Maximum induction rate of anti-inflammatory components by 
activated pro-inflammatory innate components
0.04 A-units/h
μir* Natural decay/turnover rate of resting/circulating inactivated  
pro-inflammatory innate components
0.12/h kaid* Relative effectiveness of activated pro-inflammatory innate 
components and damaged tissue/DAMPs to induce anti-
inflammatory components (A)
48.0 I-units/D-units
μI* Natural decay/turnover rate of activated pro-inflammatory innate 
components
0.05/h μa* Decay rate of anti-inflammatory components (A) 0.1/h
kid* Activation of resting/circulating pro-inflammatory innate components by 
DAMP release from damaged host and graft tissue
0.02/(D-DG)-units/h kata Maximum induction rate of anti-inflammatory components (A) by  
anti-inflammatory T cells (TA)
0.001/A-units/TA-
units/h
kitp Activation of resting/circulating pro-inflammatory innate components by 
activated/memory pro-inflammatory T cells
0.008/TP-units/h St0 Source of inactivated memory T cells 1.0 T0-units/h
kdi* Maximum rate of host tissue damage by activated pro-inflammatory  
innate components
0.35 D-units/h μt0 Decay rate of inactivated memory T cells, T0. 0.05/h
xdi* Determines level of activated pro-inflammatory innate components that 
increases damage production to half its max
0.06 I-units ktpi Maximum activation rate of memory T cells by pro-inflammatory 
innate components
0.008/I-units/h
kdgig Maximum rate of graft tissue damage by activated pro-inflammatory  
innate components 
0.35DG-units/h ktpig Maximum activation rate of memory T cells by pro-inflammatory 
innate components in the presence of allo-Ag 
0.02/I-units/h
μd* Decay rate of host and of graft tissue damage representing repair/
regeneration of injured tissue
0.02/h ktpt0g Maximum activation rate of memory T cells by alloreactive  
activated memory T cells 
0.02/h
α Scaling parameter that governs the level of apparent mismatch between 
host and graft α = 0 indicates 0% mismatch; α = 1 indicates 100% 
mismatch
α∈[0,1] 
dimension-less
μtp Decay rate of activated pro-inflammatory memory T cells 0.03/h
kdgtp Maximum rate of damage by pro-inflammatory T cells to graft tissue 
scaled by the parameter α; set to be greater than kid and kdgig to indicate 
greater potency of alloreactive T cells
0.7 DG-units/h ktaia Maximum induction of anti-inflammatory T cells by pro- and anti-
inflammatory innate components
0.04/I-units/A-units/h
xdgtp Determines the level of pro-inflammatory T cells that increases graft tissue 
damage to half its max
1 DG-units ktat0g Maximum activation rate of anti-inflammatory T cells by already 
activated alloreactive anti-inflammatory T cells
0.001/h
kgdg Tuning parameter that governs the response curve of the graft function, 
G (See Table 3)
10 dimension-less μta Decay rate of activated anti-inflammatory T cells 0.03/h
xgdg Tuning parameter that governs the response curve of the graft function, 
G (See Table 3)
0.5 DG-units b∞ Controls the strength at which the anti-inflammatory T cells (TA)  
inhibit various processes
0.5 TA-units
a∞* Controls the strength at which the anti-inflammatory components (A) 
inhibit various processes
0.28 A-units
Parameters marked with an asterisk retain the baseline value as set in (69).
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present in the DTotal/I subsystem we developed here. This means 
that the system has the ability to display different outcomes, 
depending on the initial conditions of the variables that we test. 
These outcomes are then translated qualitatively into clinical 
scenarios as discussed in Section “Results.”
Additionally, we know from the prior results that the incor-
poration of the anti-inflammatory component when treated as 
a constant will yield a loss of this bi-stability when the level of 
the anti-inflammatory component exceeds a value of 0.6264 and 
only the healthy equilibrium remains stable. Therefore, when we 
incorporate the analogous dynamic anti-inflammatory compo-
nent, A, into the full model, we wish to make sure to calibrate any 
additions to A such that the maximum level of A does not exceed 
the 0.6264 threshold, since this would produce unreasonable 
(i.e., non-biological) behavior. For instance, if this threshold were 
exceeded, the DTotal/I subsystem would be incapable of reaching 
an unhealthy equilibrium while other components of the model, 
such as activated pro-inflammatory T cells or graft damage (when 
separated from total damage), would remain elevated. The condi-
tions for bi-stability noted above will not be changed when we 
combine subsystems at the end.
The I/TP subsystem
 
dI
dt
ir ii
ir ii
i= +
−
s k I
k Iµ
µ I  (9)
 
dT
dt
P
tpi tp P= ⋅ −k T I T0 µ ,  (10)
The I/TP system has one or two non-negative equilibria depend-
ing on the parameter values. If we fix the values for the parameters 
that appeared in the DTotal/I system, the following parameters 
govern the number and stability of the equilibria: kitp, st0, μt0, ktpi. 
The point (I,TP) = (0,0) is always an equilibrium and is stable for 
kitp = 0.01, st0 = 1, μt0 = 0.05, and ktpi = 0.01. Since we have an 
estimate for the half-life of activated T cells (unpublished work) 
which translates to a rate of 0.03/h, we estimate the half-life of 
inactivated memory T cells to be slightly longer than this at 
0.05/h. Also we fix the source term, st0, to a value of 1 and then 
determine the values of kitp and ktpi such that the (0,0) equilibrium 
is stable and that the rate at which trajectories approach this 
equilibrium is not unduly slow, which is related to the position of 
the nullclines. For simplicity, we let kitp=ktpi since there is a lack of 
TaBle 5 | reactions involved in the Ir/i subsystem.
I I
k D D k I k T
R
di G ii itp P
→
+ + +( ) Activation of resting/circulating innate components, 
IR, by damaged host tissue, D, damaged graft tissue, 
DG, activated innate cells or mediators, I, and pro-
inflammatory T cells, TP
*→
sir
RI
Source of resting/circulating innate components, IR
IR
ir
→
µ Natural decay of resting/circulating innate components, IR
I →
µi Natural decay of activated innate components, I
information regarding the relative strength at which one incites 
the other. Setting the value of kitp = 0.008 = ktpi allows for each 
variable to contribute to recruiting the other by a non-negligible 
amount in this subsystem and are, as a pair of values, not too close 
to a bifurcation value where the nullclines would cross a second 
time. In other words, if their values are set to 0.01, for example, 
then (0,0) will be unstable; however, we wish for this subsystem 
to have (0,0) stable under these parameters so that neither I nor 
TP will drive sustained TP or I levels, respectively. Therefore, when 
connected to the damage equations, when each is sustained at 
an elevated equilibrium, this will depend on feedback from the 
damage they incite, rather than just each other.
The Dg/TP (and G) subsystem
 
dD
dt
G
d G dgtp P= − + ⋅µ αD k G f T( ),  (11)
 
where 
di
f x x
x x
( ) ;=
+
6
6 6
 
 
dT
dt
P
tpt0g P tp P= ⋅ ⋅ ⋅ −α µk T T G T0 .  (12)
For the DG/TP subsystem that includes the auxiliary variable G, the 
same type of functional form used in modeling damage to host 
(D) via innate cells (I) is employed to model the graft damage, DG, 
created by pro-inflammatory T cells, TP. The parameter values are 
set according to Table 4. Bi-stability is not a feature of this system, 
but when there are no TP T cells, then (0,0) is always stable; and for 
low mismatch factor (i.e., α ≤ 0.074), (0,0) is stable. As α increases 
through this, (0,0) becomes unstable and a new equilibrium of 
interest is born and is stable (spiral). For values close to 0.075, the 
approach to the equilibrium is quite slow away from the stable 
manifolds of the equilibrium. When α = 0.08, the positive equi-
librium is a stable spiral which establishes the presence of damped 
oscillations in this subsystem. Naturally, as T cells destroy graft 
tissue, there is less tissue to destroy, but as the tissue regenerates, 
the T cells can then destroy this regenerated tissue. Also, as T cell 
numbers increase the source for new ones is depleted until the 
turnover/death of existing activated T cell subsets allow for the 
activation of more (literally the way the source/recruitment term 
is modeled) – this could be interpreted as a wait time for replenish-
ment of the T cell source from the bone marrow. Understanding 
the tissue repair process and time scale relative to T cell behavior 
could help calibrate this aspect better. For instance, tissue repair/
regeneration may be hindered significantly in disease states and 
therefore may depend on the existing level of damaged tissue.
The Dg/TP/i (and g) subsystem
The DG/TP/I subsystem which includes the auxiliary variable G is 
given by Eqs 13 and 14 and displays bi-stability for the parameters 
listed in Table 4 (with α = 0). Note that the DTotal\I subsystem is 
partially contained in this 3-variable subsystem. Initial graft dam-
age values in which DG(0) > 0.095 lead to graft/host failure. Recall 
that this behavior is in the absence of any anti-inflammatory 
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inhibition; so very little graft damage can lead to failure in this 
subsystem even without a positive mismatch factor. For very low 
initial graft damage [e.g., DG(0) =  0.08 or ~2% graft damage] 
and for low graft mismatch (e.g., α = 0.01), survival is possible. 
Though the ranges of pairs of values of initial graft damage and 
α that produce survival outcomes is limited, the presence of bi-
stability exists and the presence of inhibitory components added 
later allow this range to increase. For some DG(0) and α value pairs 
[e.g., DG(0) = 0.08 and α = 0.02], graft functionality remains very 
high (~99%) for ~230 h (~1 week) after which it decreases rapidly 
to its ending steady-state functionality value of 13% by ~300 h.
If considering the presence of activated memory T cells at time 
zero [i.e., TP(0) > 0], the time to graph failure greatly decreases. 
For example with DG(0) =  0.08 and α =  0.02, when TP(0) =  1 
functionality decreases to 13% by 50 vs. 300 h without an initial 
population of activated memory T cells. A similar result occurs 
when there is an initial population of activated innate inflamma-
tory components, I. For example, with DG(0) = 0.08, α = 0.02, and 
TP(0) = 0, when I(0) = 0.01, graft functionality decreases to 13% 
by 165 vs. 300 h without an initial population of activated innate 
inflammatory components.
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anti-inflammatory effects
The parameter values for the anti-inflammatory components, 
A, were set as in Reynolds et al. where applicable and the addi-
tional parameters in this category were estimated to calibrate 
the baseline responses. For instance, the contribution of TA to 
A was calibrated such that maximum TA levels would not allow 
A to exceed its threshold value of 0.6264 as discussed previously. 
Additionally, in the case of severe initial tissue damage, it is pos-
sible that this positive feedback between DAMP release caused 
by tissue injury and inflammation causing further tissue injury 
may not resolve, and thus lead the way to multi organ failure 
and death. In the current state-of-the-art, the transplantation 
procedure and donor graft condition are such that the surgical 
procedure and associated I/R are typically not the cause of organ 
failure. However, theoretically, this scenario is possible and helps 
to calibrate the extreme cases of the model such that complete 
resolution is not the only outcome possible regardless of initial 
conditions and parameter values. Thus, the inhibitory effects of 
A and TA combined do not overly and unrealistically dampen 
the inflammatory arm of the responses. We retain the positive 
background level of the anti-inflammatory component at the 
non-perturbed healthy equilibrium, A, as set in Reynolds et al.: 
A(0) = A0 = 0.125 (69).
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